News Daily News Vast Majority of HFrEF Patients Eligible for Vericiguat L.A. McKeown February 08, 2023
News Daily News HFrEF’s Financial Burden May Get Relief From Inflation Reduction Act L.A. McKeown January 13, 2023
News Daily News Sequencing HF Meds? Most Doctors Stick to Old Habits, Survey Says Todd Neale December 08, 2022
News Conference News AHA 2022 STRONG-HF: Rapid Uptitration of GDMT After Acute HF Pays Dividends Todd Neale November 07, 2022
News Conference News HFSA 2022 Dapagliflozin’s Benefits Similar in HF Patients With Improved EF: DELIVER Todd Neale October 04, 2022
News Conference News ESC 2022 ARBs Halve Rate of Aortic Root Enlargement in Marfan: Meta-analysis Shelley Wood August 29, 2022
News Daily News Dapagliflozin Safe, Effective in Diabetes Regardless of Background CV Meds Shelley Wood July 25, 2022
News Daily News LVEF Analysis Digs Anew Into Revascularization Benefits in Ischemic CAD Michael O'Riordan July 11, 2022
News Daily News Quadruple Therapy Costs Prohibitive for Many HFrEF Patients L.A. McKeown June 21, 2022
News Conference News ESC Heart Failure 2022 HF Triple Therapy Doesn’t Seem Effective in True Preserved HF Shelley Wood May 25, 2022
News Conference News HRS 2022 Gains in HF Drug Therapy Raise Questions About ICD Benefit in Modern Era Todd Neale May 02, 2022
News Daily News Underuse of GDMT for Heart Failure Even Worse in Low-Income Countries Todd Neale April 20, 2022
News Conference News ACC 2022 PROMPT-HF: Pop-up Alerts Improve HFrEF Medication Optimization L.A. McKeown April 03, 2022
News Conference News ACC 2022 New HF Guidelines Stress Four-Drug Approach, ‘HFmrEF,’ Amyloidosis Options, and More Shelley Wood April 01, 2022
News Features Four Pillars, Fast? Rapid Sequencing of HF Drugs Faces an Uphill Battle Shelley Wood October 08, 2021
News Conference News HFSA 2021 Digital App Improves HF Quality-of-Care Metrics: CONNECT-AF Michael O'Riordan September 14, 2021
Presentation ESC 2021 Continuing versus Suspending Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers:Impact on Adverse Outcomes in Hospitalized Patients with Severe Acute Respiratory Distress Syndrome Coronavirus 2 (SARS-CoV-2 Presenter: Renato D. Lopes August 30, 2021
News Conference News ESC 2021 New ESC HF Guidelines Showcase SGLT2 Inhibitors, Tafamidis, Vericiguat, and COAPT Shelley Wood August 28, 2021
News Daily News Dapagliflozin US Cost-effectiveness Data Expose Barriers to HF Care Shelley Wood May 27, 2021